Vaxcyte, Inc. (NASDAQ:PCVX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have earned a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $106.25.

A number of research analysts have recently issued reports on PCVX shares. Cowen reaffirmed a “buy” rating on shares of Vaxcyte in a research report on Thursday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Tuesday, October 14th. Finally, The Goldman Sachs Group initiated coverage on Vaxcyte in a research report on Friday, September 12th. They set a “neutral” rating and a $38.00 price target on the stock.

Vaxcyte Price Performance

Shares of NASDAQ PCVX opened at $41.71 on Friday. The stock has a market capitalization of $5.46 billion, a P/E ratio of -8.62 and a beta of 1.07. Vaxcyte has a 1-year low of $27.66 and a 1-year high of $107.31. The business has a fifty day moving average price of $37.88 and a 200 day moving average price of $34.91.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, November 4th. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.29). During the same quarter in the prior year, the firm posted ($0.83) earnings per share. As a group, equities research analysts anticipate that Vaxcyte will post -4.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vaxcyte

Hedge funds and other institutional investors have recently modified their holdings of the stock. AlphaQuest LLC grew its position in Vaxcyte by 147.1% during the 3rd quarter. AlphaQuest LLC now owns 10,946 shares of the company’s stock worth $394,000 after purchasing an additional 6,517 shares during the last quarter. Arizona State Retirement System lifted its stake in shares of Vaxcyte by 1.6% during the third quarter. Arizona State Retirement System now owns 34,333 shares of the company’s stock worth $1,237,000 after buying an additional 543 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Vaxcyte by 64.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 23,184 shares of the company’s stock valued at $835,000 after buying an additional 9,074 shares during the last quarter. Federated Hermes Inc. increased its position in shares of Vaxcyte by 6,856.3% in the 3rd quarter. Federated Hermes Inc. now owns 18,156 shares of the company’s stock valued at $654,000 after acquiring an additional 17,895 shares during the period. Finally, Vanguard Personalized Indexing Management LLC increased its position in shares of Vaxcyte by 24.6% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 15,855 shares of the company’s stock valued at $571,000 after acquiring an additional 3,133 shares during the period. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.